GILUPI

Claim instruction:

Send us an email to claim@startus.cc from an official GILUPI  email account. The content must be:

StartUs buddies,

Please, allow me to claim rights over GILUPI .

Best regards,
[your name]
Once sent the email click the Claim Startup button.
Our team will verify the origin account and will grant claim rights over the startup to the user if everything is ok.

https://www.startus.cc/company/gilupi

Hermannswerder 20a

14473 Potsdam

Germany

Website

General information:

Our innovative medical devices, the GILUPI CellCollectors, enable the detection of rare cells directly from the blood of patients. The target cells (e.g. circulating tumor cells - CTCs in oncology) are obtained by in vivo cell isolation. The isolated cells can be characterized at the molecular level. This provides information to the doctors to treat their patients with individual therapies. In oncology, GILUPI’s CellCollector®products enable physicians to monitor the disease of their patients during therapy, and after completion of cancer medication. Besides the use in oncology, it will be possible in the near future to use different devices in other clinical applications. Isolation devices for other rare cells in cardiovascular disease or certain bacteria in severe infection and sepsis are in development.

Company information:

Company type:

Startup

Industry:

Healthcare / Medical Services

Products and Services:

GILUPI CellCollector

Product category:

Medical devices

The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide which is CE approved.

The GILUPI CellCollector® has been deployed in more than 1800 patients, the results of lung, prostate, breast and colorectal cancer patients indicate consistent and high CTC detection rates and cell numbers (similar for early and late cancer stages). The GILUPI CellCollector® has a high CTC detection rate of 70% in early and 72% in late cancer stages.

GILUPI

Contact:

Address information